devimistat
Small moleculeexperimental
Clinical trial activity
28 trials · 16 clinical orgs · 0 marketing orgs
Phase 1
18
Phase 2
17
Phase 3
1
Phase 4
0
Earliest trial started Aug 1, 2008 (NCT00741403)
Timeline
Indications
Studied for
- Adenocarcinoma · Phase 1
- Bile Duct Neoplasms · Phase 1/Phase 2
- Biliary Tract Neoplasms · Phase 2
- Burkitt Lymphoma · Phase 1
- Carcinoma · Phase 2
- Carcinoma, Non-Small-Cell Lung · Phase 1/Phase 2
- Carcinoma, Transitional Cell · Phase 2
- Cholangiocarcinoma · Phase 1/Phase 2
- Colonic Neoplasms · Phase 1
- Colorectal Neoplasms · Phase 2
- Drugs, Investigational · Phase 1
- Esophageal Neoplasms · Phase 2
- Gallbladder Neoplasms · Phase 1/Phase 2
- Hodgkin Disease · Phase 1
- Intraocular Lymphoma · Phase 1
- Leukemia · Phase 2
- Leukemia, Hairy Cell · Phase 1
- Leukemia, Large Granular Lymphocytic · Phase 1
- Leukemia, Lymphocytic, Chronic, B-Cell · Phase 1
- Leukemia-Lymphoma, Adult T-Cell · Phase 1
- Leukemia, Myeloid, Acute · Phase 3
- Liver Neoplasms · Phase 1/Phase 2
- Lung Neoplasms · Phase 2
- Lymphoma · Phase 2
- Lymphoma, B-Cell, Marginal Zone · Phase 1
- Lymphoma, Follicular · Phase 1
- Lymphoma, Large-Cell, Anaplastic · Phase 1
- Lymphoma, Large-Cell, Immunoblastic · Phase 1
- Lymphoma, Mantle-Cell · Phase 1
- Lymphoma, Non-Hodgkin · Phase 1
- Lymphoma, T-Cell · Phase 1
- Lymphoma, T-Cell, Peripheral · Phase 1
- Lymphomatoid Granulomatosis · Phase 1
- Myelodysplastic Syndromes · Phase 2
- Neoplasms · Phase 2
- Ovarian Neoplasms · Phase 2
- Pancreatic Neoplasms · Phase 2
- Precursor B-Cell Lymphoblastic Leukemia-Lymphoma · Phase 1
- Sarcoma, Clear Cell · Phase 1/Phase 2
- Sarcoma, Myeloid · Phase 2
- Sezary Syndrome · Phase 1
- Small Cell Lung Carcinoma · Phase 1
- Testicular Neoplasms · Phase 1
- Waldenstrom Macroglobulinemia · Phase 1
Mechanism of action
- Pyruvate dehydrogenase kinaseINHIBITOR
Pyruvate dehydrogenase kinase inhibitor
- [Pyruvate dehydrogenase (acetyl-transferring)] kinase isozyme 2, mitochondrial (PDK2) ↗
- [Pyruvate dehydrogenase (acetyl-transferring)] kinase isozyme 3, mitochondrial (PDK3) ↗
- [Pyruvate dehydrogenase (acetyl-transferring)] kinase isozyme 4, mitochondrial (PDK4) ↗
- [Pyruvate dehydrogenase (acetyl-transferring)] kinase isozyme 1, mitochondrial (PDK1) ↗
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- 6,8-bis(benzylthio)octanoic acid
- 6,8-bis(benzylthio)octanoic acid
- cpi613
- cpi 613
- cpi 613
- cpi-613
- cpi-613
- cpi-613
- cpi-613
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06518538 | Phase 2 | Aug 15, 2024 | Rafael Pharmaceuticals Inc. |
| NCT05926206 | Phase 1/Phase 2 (Phase 2) | Jul 31, 2023 | University of Michigan |
| NCT05733000 | Phase 2 | Mar 8, 2023 | National Cancer Institute (NCI), Northwestern University |
| NCT05325281 | Phase 1 | Oct 31, 2022 | Medical College of Wisconsin, Rafael Pharmaceuticals Inc. |
| NCT05070104 | Phase 1 | Jan 30, 2022 | Rafael Pharmaceuticals Inc. |
| NCT04593758 | Phase 1/Phase 2 (Phase 2) | Dec 1, 2020 | Rafael Pharmaceuticals Inc. |
| NCT03929211 | Phase 1/Phase 2 (Phase 2) | Aug 31, 2019 | National Cancer Institute (NCI), Wake Forest University |
| NCT03793140 | Phase 2 | Dec 31, 2018 | City of Hope National Medical Center, George Washington University, Harvard University, Memorial Sloan-Kettering Cancer Center, University of Texas at Houston |
| NCT03504410 | Phase 3 | Oct 31, 2018 | Rafael Pharmaceuticals Inc., University of Texas at Houston |
| NCT03374852 | Phase 2 | Aug 31, 2018 | Rafael Pharmaceuticals Inc., Thomas Jefferson University |
| NCT03370159 | Phase 1/Phase 2 (Phase 2) | Jun 30, 2018 | National Cancer Institute (NCI), Wake Forest University |
| NCT01520805 | Phase 2 | Jan 1, 2016 | Rafael Pharmaceuticals Inc. |
| NCT02472626 | Phase 1/Phase 2 (Phase 2) | Dec 1, 2015 | National Cancer Institute (NCI), Wake Forest University |
| NCT02484391 | Phase 2 | Sep 1, 2015 | National Cancer Institute (NCI), Wake Forest University |
| NCT02232152 | Phase 1 | Dec 1, 2014 | National Cancer Institute (NCI), Wake Forest University |
| NCT02168907 | Phase 1 | Dec 1, 2014 | National Cancer Institute (NCI), Wake Forest University |
| NCT02168140 | Phase 1 | Sep 1, 2014 | National Cancer Institute (NCI), Wake Forest University |
| NCT01830322 | Phase 2 | Jan 1, 2014 | Rafael Pharmaceuticals Inc. |
| NCT01931787 | Phase 1 | Oct 1, 2013 | National Cancer Institute (NCI), Wake Forest University |
| NCT01902381 | Phase 2 | Aug 1, 2013 | National Cancer Institute (NCI), Wake Forest University |
Showing 20 of 28 trials
Page 1 / 2
Organizations
Research & Development (16)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| National Cancer Institute (NCI) | Government | 14 | 0 | 2 | 2013 |
| Wake Forest University | Academic/Hospital | 14 | 14 | 2 | 2010 |
| Rafael Pharmaceuticals Inc. | For profit | 11 | 9 | 3 | 2008 |
| Eastchester Center for Cancer Care | Academic/Hospital | 2 | 0 | 2 | 2008 |
| Mary Crowley Cancer Center | Academic/Hospital | 2 | 0 | 2 | 2008 |
| University of Texas at Houston | Academic/Hospital | 2 | 0 | 2 | 2018 |
| British Columbia Cancer Agency | Academic/Hospital | 1 | 0 | 1 | 2008 |
| City of Hope National Medical Center | Academic/Hospital | 1 | 0 | 1 | 2018 |
| George Washington University | Academic/Hospital | 1 | 0 | 1 | 2018 |
| Harvard University | Academic/Hospital | 1 | 0 | 1 | 2018 |
| Medical College of Wisconsin | Academic/Hospital | 1 | 1 | 1 | 2022 |
| Memorial Sloan-Kettering Cancer Center | Academic/Hospital | 1 | 1 | 1 | 2018 |
| Northwestern University | Academic/Hospital | 1 | 1 | 1 | 2023 |
| Pivotal Research Centers | For profit | 1 | 0 | 1 | 2008 |
| Thomas Jefferson University | Academic/Hospital | 1 | 1 | 1 | 2018 |
| University of Michigan | Academic/Hospital | 1 | 1 | 1 | 2023 |
16 organizations
Page 1 / 1